Figure 1: Continuous treatment with bevacizumab induces acquired resistance in vivo.
From: Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
(a) The survival curve of tumour-bearing mice treated with bevacizumab (bev) beginning from seven days after tumour cell injection. (left) Human MPM cell lines (Y-MESO-14 and EHMES-10) were injected orthotopically. (right) Human lung cancer cell lines (PC14PE6 and A549) were injected via the tail vein. (b) The weights of Y-MESO-14 intrathoracic tumours from the control and bevacizumab (bev)-treated groups at different time points. (c) Representative images of sections from Y-MESO-14 intrathoracic tumours stained for CD31. The tumours were harvested at different time points from the control and bevacizumab (bev)-treated groups. Scale bar, 200 μm. (d) Quantitative evaluation of MVD (quantified as the total number of CD31+ structures/HPF) in each tumour of mice (n=5 per group) studied in c. The data are shown as the means±s.e.m *P<0.05 by a one-way ANOVA.
